Rapid communication Open Access
Like 0


Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.


Article metrics loading...

Loading full text...

Full text loading...



  1. European Centre for Disease Prevention and Control (ECDC). Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – ninth update, 23 April 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf
  2. Eurosurveillance Editorial Team. Latest updates on COVID-19 from the European Centre for Disease Prevention and Control. Euro Surveill. 2020;25(6):2002131. PMID: 32070466 
  3. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic. Geneva: WHO. [Accessed 28 Mar 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  4. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9):2000178.  https://doi.org/10.2807/1560-7917.ES.2020.25.9.2000178  PMID: 32156327 
  5. World Health Organization (WHO). Laboratory testing of 2019 novel coronavirus (‎‎‎‎‎‎‎‎‎‎‎‎2019-nCoV)‎‎‎‎‎‎‎‎‎‎‎‎ in suspected human cases: interim guidance, 17 January 2020. Geneva: WHO; 17 Jan 2020.
  6. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.  https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045  PMID: 31992387 
  7. Okba NMA, Muller MA, Li W, Wang C, Geurtsvankessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. preprint doi:
  8. Amanat F, Nguyen T, Chromikova V, Strohmeier S, Stadlbauer D, Javier A, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. preprint doi:  https://doi.org/10.1101/2020.03.17.20037713 
  9. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant. 2020;39(5):405-7.  https://doi.org/10.1016/j.healun.2020.03.012 
  10. World Health Organization (WHO). Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Geneva: WHO; 20 Mar 2020. Available from: https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)
  11. Okba NMA, Raj VS, Widjaja I, GeurtsvanKessel CH, de Bruin E, Chandler FD, et al. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. Emerg Infect Dis. 2019;25(10):1868-77.  https://doi.org/10.3201/eid2510.190051  PMID: 31423970 
  12. Nicastri E, D’Abramo A, Faggioni G, De Santis R, Mariano A, Lepore L, et al. , On Behalf Of Inmi And The Italian Army Covid-Study Groups. Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020. Euro Surveill. 2020;25(11):2000230.  https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000230  PMID: 32209164 
  13. Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25(11):2000266.  https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000266  PMID: 32209163 

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error